Background: Circular RNAs (circRNAs), a type of noncoding RNA, are associated with the occurrence and development of cancers. In recent years, their potential as biomarkers for bladder cancer (BC) has attracted increased attention.
Intravesical instillation therapy is the mainstay of prophylaxis of tumor recurrence and progression in non-muscle-invasive bladder cancer. However, there is no study evaluating the superiority of monotherapy.
Over the last two decades, active surveillance (AS) has been established as a treatment strategy for favorable prostate cancers. This strategy is indicated for insignificant cancer, which is typically indolent with limited potential to progress and will not threaten life prognosis in the future. AS is a practical solution to avoid overtreatment for such insignificant […]
For 40 years intravesical Bacillus Calmette-Guérin (BCG) instillation has been used as a non-specific immunotherapy to recruit immune cells into the bladder to reduce the recurrence and progression rates of high-risk nonmuscle-invasive bladder cancer (NMIBC).1 Unfortunately, the failure rate was close to 50% and the immune escape mechanism of cancer cells remained long misunderstood.2 However, […]
San Francisco, CA (UroToday.com) — Monash University’s Precision Medicine research group has discovered multiple new genetic risk factors that make men susceptible to aggressive prostate cancer that will contribute to the future prevention of the disease.
The COVID-19 pandemic has resulted in numerous physical and psychological adjustments for clinicians, patients, and their families—wearing personal protective equipment, adopting telemedicine, adjusting clinic workflow, etc. The ensuing uncertainty and attendant anxiety from the fluidity of information and healthcare policy debate has augmented the need for enhanced communication and thoughtfulness for healthcare providers. For urologic […]
Phase I trial first to evaluate neoadjuvant combination immunotherapy for cisplatin-ineligible patients with high-risk disease San Francisco, CA (UroToday.com) — Neoadjuvant, or pre-surgical, combination treatment with the immune checkpoint inhibitors tremelimumab (anti-CTLA-4) and durvalumab (anti-PD-1) was well-tolerated and showed early signs of activity in certain patients with localized bladder cancer who do not have standard treatment options available, according to […]
Immune checkpoint therapy is being tested in the neoadjuvant setting for patients with localized urothelial carcinoma1,2, with one study reporting data in cisplatin-ineligible patients who received anti-PD-L1 monotherapy2. The study reported that patients with bulky tumors, a known high-risk feature defined as greater than clinical T2 disease, had fewer responses, with pathological complete response rate […]
Chris Wallis: Hello, and thank you for joining us for this UroToday Journal Club. Today we’re discussing a recent publication from the CARD trial entitled “Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide”. This was a randomized multicenter open-label phase 4 trial. I’m Chris Wallis, a fellow […]
– Durable Responses Observed in Patients Who Had Previously Received Immunotherapy but Were Ineligible for Cisplatin in Locally Advanced or Metastatic Setting – San Francisco, CA (UroToday.com) — Astellas Pharma Inc. President and CEO: Kenji Yasukawa, Ph.D. and Seagen Inc. announced positive topline results from the second cohort of patients in the pivotal phase 2 single-arm clinical […]
